Entera Bio Ltd. ENTX 深 沪
已收盘 11-07 16:00:00 美东时间
3.14
+0.030
+0.96%
华盛通- 最 高3.15
- 今 开3.10
- 成交量 12.96万股
- 最 低 3.0007
- 昨 收 3.11
- 总市值 1.43亿
- 52周最高 3.22
- 市盈率 静 --
- 换手率 0.28%
- 52周最低 1.5006
- 委 比 -88.56%
- 总股本 4566.34万
- 历史最高 10.16
- 量 比 0.56
- 振 幅 4.80%
- 历史最低 0.472
- 每 手 1
- 风险率 0.28%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Entrada Therapeutics to Present at Upcoming Investor Conferences
Entrada Therapeutics announced its participation in two upcoming investor conferences. CEO Dipal Doshi will present at the Jefferies Global Healthcare Conference in London on November 18 and will join a fireside chat at the Evercore Healthcare Conference in Miami on December 3. Live webcasts and 90-day replays will be available on the company's website. Entrada, a clinical-stage biopharmaceutical company, develops novel intracellular therapies fo...
10-28 11:00
Entera Bio Releases New Phase 2 Data At NAMS 2025 Showing That EB613, An Oral PTH[1-34] Therapy, Consistently Increased Bone Mineral Density In Both Early Postmenopausal Women And Those 10 Years Post-Menopause
Consistency of BMD gains presented at NAMS 2025 demonstrate EB613's efficacy in both young postmenopausal women and in women 10 years post-menopauseData further support EB613 potential as a first-in-class oral anabolic
10-23 20:58
Entera Bio Presents Positive New Clinical Data from EB613 Phase 2 Trial Demonstrating Significant Bone Density Improvements in Early Postmenopausal Women
<p>Entera Bio的EB613在NAMS 2025会议上展示了其在早期和更晚更年期女性中的BMD提升效果，表明其作为首个口服骨形成疗法的潜力，可显著扩大患者对骨疗法的可及性。Entera计划在2025年7月FDA同意后启动全球注册性III期研究。EB613在II期试验中显示，2.5 mg剂量在早期更年期女性脊柱、股骨颈和髋部BMD有显著提升，效果与晚期更年期女性相当。该产品有望改变骨质疏松治疗方式，提高患者依从性，并有望成为首个口服骨形成治疗选项。</p>
10-23 12:50
Entera Bio Announces It Will Present New Phase 2 Clinical Data For EB613 At The North American Menopause Society 2025 Annual Meeting, October 21–25, 2025, In Orlando, Florida.
Entera Bio Ltd. (NASDAQ:ENTX), a leader in the development of oral peptide and protein replacement therapies, today announced that it will present new clinical data from its Phase 2 trial of EB613 at the upcoming North
10-16 20:47
Entera Bio to Present New Clinical Data from Phase 2 Trial of EB613 at the 2025 North American Menopause Society (NAMS) Annual Meeting
Entera Bio will present Phase 2 data for EB613 at the NAMS 2025 Annual Meeting, focusing on bone mineral density outcomes in early postmenopausal women with low bone mass or osteoporosis. EB613, the first oral anabolic tablet, aims to address the underutilization of injectable anabolic therapies by providing a once-daily treatment option. The study met all biomarker and BMD endpoints, demonstrating increases in lumbar spine, total hip, and femora...
10-16 12:45
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Genprex (NASDAQ:GNPX) stock increased by 88.1% to $0.47 during Wednesd...
10-15 20:09
Entera Bio Presents Preclinical Data For OPK-8801003, Oral GLP-2 Tablet With Longer Half-Life Aiming To Replace Daily Injections For Short Bowel Syndrome Patients
Preclinical Data for OPK-8801003 Demonstrate Substantially Longer Biological Half-Life with Peak Plasma Levels Comparable to Gattex®, the Only Approved GLP-2 TherapyOral GLP-2 Tablet Could Transform Treatment
09-15 21:05
Entera Bio To Present EB613 Phase 2 Data At ASBMR 2025; Oral Anabolic Tablet Advances Toward Phase 3
EB613 Demonstrates Significant Effects on Both Trabecular and Cortical Bone Compartments After Just 6 Months of Treatment in Phase 2 Study; Cortical Improvements Comparable to Injectable Teriparatide and
09-08 20:33
Entrada Therapeutics Announces Recipients of Third Annual DREAMS Grant Program
Entrada Therapeutics announced the recipients of its 2025 DREAMS Grant Program, awarding $50,000 each to Jett Foundation (U.S.) and Parent Project aps (Italy). These grants support programs advancing equity, accessibility, and inclusion for individuals with Duchenne muscular dystrophy in the U.S., EU, and U.K. Jett Foundation's Camp Promise provides year-round support for underserved individuals aged 18 and older, while Parent Project aps deliver...
09-05 11:00
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Entrada Therapeutics granted 54,360 RSUs and options to purchase 38,850 shares to seven newly-hired employees under its 2025 Inducement Equity Plan. Options have an exercise price of $5.47 per share, vesting 25% after the first year, with the remaining 75% vesting monthly over three years. RSUs vest 25% after the first year, followed by 6.25% quarterly. The grants aim to incentivize new employees, as approved by the Compensation Committee.
09-02 20:30
